An FDA-guided and -supervised study revealed that microcurrent stimulation, also called electrotherapy, resulted in significant vision improvements in 61% of patients suffering from dry macular degeneration. The research showed promise that microcurrent stimulation could also help patients with diabetic retinopathy or retinitis pigmentosa.
Microcurrent stimulation is a therapy designed to alleviate pain, promote the healing of wounds and improve results with transplanted tissues. The FDA has approved its use for these purposes under specific protocols. This therapy is commonly used by rehab specialists, anesthesiologists, orthopedic surgeons, and plastic surgeons.
Using a variation on these protocols, researchers at the Department of Pediatrics, Pulmonary Disease & Critical Care, in Minneapolis, Minnesota measured the visual acuity of 400 patients with dry macular degeneration using the Snellen chart (above). The average electric current intensities that resulted in the best improvements ranged from 60 muA – 125 muA. The scientists found that 61% of the patients had improvements of two or more lines on the Snellen chart.
The scientists deduced that long-term visual acuity improvements of two or more lines on the chart could be expected for 60% or more of patients in early-stage dry macular degeneration, retinitis pigmentosa, and diabetic retinopathy. They believe that refining the microcurrent stimulation equipment and protocols are key to achieving improved and consistent results.
Editor’s Note: The reasons why electrotherapy is effective for certain eye diseases is not well understood scientifically. One theory is that it re-stimulates and energizes dormant retinal cells. It may increase cells’ ability to remove waste products that interfere with nutrition, energy flow, or cellular communication. Also, microcurrent stimulation may increase the supply of blood to the area refreshing and nourishing living tissues and cells.
At Natural Eye Care, we offer a microcurrent stimulation 100ile device for lease-to-own or for sale. Patients who want to try the device and see how well it works for them often opt to lease the device for several months. If they lease the device for 8 months, it is considered paid. Buying the microcurrent stimulation 100ile device from us outright is $100 cheaper.
- Electrotherapeutic device/protocol design considerations for visual disease applications
- E. C. Kondrot, Improvement in Vision Parameters for Participants Treated With Alternative Therapies in a 3-day Program, Alternative Therapies in Health and Medicine, November, 2015
Kai Shinoda, et al, Transcutaneous Electrical Retinal Stimulation Therapy for Age-Related Macular Degeneration, Open Opthamology Journal, August, 2008.
- Also see other research.